FDA rejects plan to expand use of Astex blood cancer drug

The Food and Drug Administration Tuesday rejected an attempt to expand the use of the blood cancer drug Dacogen, developed by Dublin’s Astex Pharmaceuticals Inc.
An FDA advisory panel last month recommended that the agency not approve the application by Eisai Co., which markets the drug in the United States.